Stay updated on Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe revision label at the bottom of the page updated from v3.3.1 to v3.3.2, which is a UI/version detail and does not affect study data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedThe record history now includes Revision: v3.3.1 and removes Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedA government funding/status notice that previously appeared on the page has been removed; the overall history content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check42 days agoChange DetectedNew screenshot shows the same version history entries with only minor visual adjustments to headers and spacing; no core data or version entries were added or removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check71 days agoChange DetectedMajor update: new operating-status notice and a v3.2.0 version release, replacing the prior v3.1.0.SummaryDifference10%

- Check78 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.3%

Stay in the know with updates to Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.